Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

NCT04326036 is registered in ClinicalTrials.gov with Black Tie Medical, Inc. as lead sponsor.

NCT NCT04326036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04326036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection
Lead sponsor
Black Tie Medical, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 25, 2020
Completion date
January 31, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

copd, coronavirus infection, idiopathic pulmonary fibrosis, interstitial lung disease, pulmonary alveolar proteinosis, viral pneumonia